Are Drug-Eluting Stents in Trouble?

Doctors are using drug-eluting stents less and turning to their bare metal counterparts more often, according to consulting firm Goodroe Healthcare Solutions LLC. Part of this could be due to studies that have revealed a potential link between bloot clots and drug-eluting stents. The Boston Globe reports that although the shift is small, it could still hurt the revenues of companies like Boston Scientific and Johnson & Johnson.

October 18, 2006

1 Min Read
Are Drug-Eluting Stents in Trouble?

It mentions that Boston Scientific informed Wall Street that its stent sales for the third quarter of 2006 could drop as much as $50 million from the previous year. Johnson & Johnson's rival Cypher stent also saw a decrease in third quarter sales--down six percent from the same quarter last year, and it's international sales fell three percent.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like